Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1994-2-7
pubmed:abstractText
Dermatan sulphate (DS) obtained from bovine and pig mucosa and pig skin, and charge-enriched fractions of a selected DS preparation, were characterized in terms of charge density, M(r) and disaccharide composition of chondroitin ABC lyase digests, and by 13C-n.m.r. spectroscopy. Besides the major IdoA-GalNAc4SO3 sequences, all DS preparations contain about 10% disulphated disaccharide sequences (mostly IdoA2SO3-GalNAc4SO3, with minor amounts of IdoA-GalNAc4,6SO3). DS fragments (prepared by radical-catalysed depolymerization of DS and retaining the internal structure of the parent polysaccharide) as well as Smith degraded fragments [SD-DS, obtained by controlled degradation of periodate-oxidized and borohydride-reduced DS (RO-DS)] with the general structure GalNAc4SO3(IdoA2SO3-GalNAc4SO3)n-R (where R is the remnant of a glycol-split uronic acid, and n = 2-3 and 3-4) were characterized by one- and two-dimensional 1H-n.m.r., 13C-n.m.r. and disaccharide composition analysis. In accordance with previous findings [Maimone and Tollefsen (1990) J. Biol. Chem. 265, 18263-18271], only fragments with n > or = 3 significantly enhance the heparin cofactor II-mediated inhibition of thrombin. In natural DS preparations and their fractions, this activity (as well as the antithrombotic activity in an animal model) appears to require IdoA2SO3-containing sequences. The heparin cofactor II activity of DS, RO-DS and SD-DS fragments decreases with decreasing M(r). However, RO-DS fragments are more active than DS fragments of similar M(r), probably because of the extra flexibility endowed by glycol-split IdoA residues.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-143898, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-1442260, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-1930287, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-2211700, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-2339978, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-2432917, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-2499215, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-2500236, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-2525356, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-2660681, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-2735661, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-2902851, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-2930454, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-2972560, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-3076283, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-3198623, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-3217919, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-3306287, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-3401503, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-354500, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-3620505, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-3698057, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-4371969, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-4371970, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-6547786, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-6687888, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-7414553, http://linkedlifedata.com/resource/pubmed/commentcorrection/8280062-8461463
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0264-6021
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
296 ( Pt 3)
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
639-48
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
Structure and contribution to the heparin cofactor II-mediated inhibition of thrombin of naturally oversulphated sequences of dermatan sulphate.
pubmed:affiliation
Opocrin S.p.A. Research and Development Laboratories, Corlo di Formigine, Modena, Italy.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't